Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - vosevi
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp9648a8c3d3b260e0c01496efb4b0ef56
identifier: http://ema.europa.eu/identifier
/EU/1/17/1223/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Vosevi 400 mg/100 mg/100 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-9648a8c3d3b260e0c01496efb4b0ef56
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/17/1223/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - vosevi
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
If Vosevi has been prescribed for your child, please note that all the information in this leaflet is addressed to your child (in this case please read your child instead of you ).
What is in this leaflet
Vosevi is a medicine that contains the active substances sofosbuvir, velpatasvir and voxilaprevir in a single tablet. It is given to treat a chronic (long-term) viral infection of the liver called hepatitis C in patients aged 12 years and older and weighing at least 30 kg.
The active substances in this medicine work together by blocking three different proteins that the hepatitis C virus needs to grow and reproduce itself, causing the infection to be eliminated from the body.
Do not take Vosevi
If you are allergic to sofosbuvir, velpatasvir, voxilaprevir or any of the other ingredients of this medicine (listed in section 6 of this leaflet).
If this applies to you, do not take Vosevi and tell your doctor immediately.
If you are currently taking any of the following medicines:
rifampicin and rifabutin (antibiotics used to treat infections, including tuberculosis);
St. John s wort (Hypericum perforatum) (a herbal medicine used to treat depression);
carbamazepine, phenobarbital and phenytoin (medicines used to treat epilepsy and prevent seizures);
rosuvastatin (a medicine used to treat high blood cholesterol or decrease the risk of certain cardiovascular events);
dabigatran etexilate (a medicine used to prevent blood clots);
ethinylestradiol containing medicines, including many contraceptives. Warnings and precautions
Talk to your doctor if you:
Talk to your doctor or pharmacist before taking Vosevi if:
Tell your doctor immediately if you currently take, or have taken in the last months, any medicines for heart problems and during treatment you experience:
Blood tests
Your doctor will test your blood before, during and after your treatment with Vosevi. This is so that:
Children and adolescents
Do not give this medicine to children under 12 years of age and weighing less than 30 kg. The use of Vosevi in these patients has not yet been studied.
Other medicines and Vosevi
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
If you are not sure talk to your doctor or pharmacist.
Some medicines must not be taken with Vosevi. Taking Vosevi with any of these may stop your medicines from working properly, or make any side effects worse:
Tell your doctor or pharmacist if you are taking any of the medicines below:
amiodarone, used to treat irregular heartbeats;
rifapentine (an antibiotic used to treat infections, including tuberculosis);
oxcarbazepine (medicine used to treat epilepsy and prevent seizures);
tenofovir disoproxil fumarate, or any medicine containing tenofovir disoproxil fumarate, used to treat HIV infection;
atazanavir, efavirenz or lopinavir, used to treat HIV infection;
digoxin, used to treat heart conditions;
modafinil, used to treat sleep disorders;
atorvastatin, pravastatin, or other statins, used to treat high cholesterol;
ciclosporin, used to suppress the immune system. Taking Vosevi with any of these may stop your medicines from working properly, or make any side effects worse. Your doctor may need to give you a different medicine or adjust the dose of medicine you are taking.
Get advice from a doctor or pharmacist if you take medicines used to treat stomach ulcers, heartburn or acid reflux as they can decrease the amount of velpatasvir in your blood. These medicines include:
antacids (such as aluminium/magnesium hydroxide or calcium carbonate). These should be taken at least 4 hours before or 4 hours after Vosevi;
proton pump inhibitors (such as omeprazole, lansoprazole, rabeprazole, pantoprazole and esomeprazole). If you need high doses of these medicines your doctor may give you a different medicine instead or adjust the dose of the medicine you are taking;
H2-receptor antagonists (such as famotidine, cimetidine, nizatidine or ranitidine). If you need high doses of these medicines your doctor may give you a different medicine instead or adjust the dose of the medicine you are taking. These medicines can decrease the amount of Vosevi in your blood. If you are taking one of these medicines your doctor will either give you a different medicine for stomach ulcers, heartburn or acid reflux, or recommend how and when you take that medicine.
Get advice from a doctor or pharmacist if you take warfarin or other similar medicines called vitamin K antagonists used to thin the blood. Your doctor may need to increase the frequency of your blood tests to check how well your blood can clot.
Your liver function may change with treatment of hepatitis C and therefore may affect other medicines (e.g. medicines used to suppress your immune system, etc.). Your doctor may need to closely monitor these other medicines you are taking and make adjustments after starting Vosevi.
Pregnancy, breast-feeding and fertility
If you are pregnant, think you may be pregnant, are breast-feeding your baby, or are planning to have a baby ask your doctor for advice before taking this medicine.
Pregnancy
Vosevi is not recommended during pregnancy. The effects of Vosevi during pregnancy are not known.
Breast-feeding
Do not breast-feed during treatment with Vosevi. Some of the active substances of Vosevi may pass into human breast milk.
Driving and using machines
Vosevi should not affect your ability to drive or use any tools or machinery.
Vosevi contains lactose
Tell your doctor if you are lactose intolerant or intolerant to other sugars. Vosevi contains lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars contact your doctor before taking this medicine.
Vosevi contains sodium This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium free .
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Recommended dose
The recommended dose of Vosevi is one 400 mg/100 mg/100 mg tablet or two 200 mg/50 mg/50 mg tablets, taken once a day for 8 or 12 weeks.
Take Vosevi as advised by your doctor.
Swallow the tablet(s) whole with food. Do not chew, crush or split the tablet as it has a very bitter taste.
Kidney problems
Tell your doctor if you have kidney problems or if you are on kidney dialysis, since Vosevi has not been fully tested in patients with severe kidney problems.
Liver problems
Vosevi should not be used if you have moderate or severe liver problems.
If you are taking an antacid, take it at least 4 hours before or at least 4 hours after Vosevi.
If you are sick (vomit) after taking Vosevi it may affect the amount of Vosevi in your blood. This may make Vosevi work less well.
If you take more Vosevi than you should
If you accidentally take more than the recommended dose of Vosevi you may be at increased risk of side effects with this medicine (see section 4 Possible side effects).
Contact your doctor or nearest emergency department immediately for advice. Keep the tablet bottle with you so that you can easily describe what you have taken.
If you forget to take Vosevi
It is important not to miss a dose of this medicine.
If you do miss a dose, work out how long it is since you last took your Vosevi:
Do not stop taking Vosevi
Do not stop taking this medicine unless your doctor tells you to. It is very important that you complete the full course of treatment to give the medicine the best chance to treat your hepatitis C virus infection.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everybody gets them.
Some side effects could be serious
Stop taking Vosevi and seek medical help immediately if you experience any of the following symptoms:
Other side effects that may occur
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle and carton after EXP . The expiry date refers to the last day of that month.
This medicine does not require any special temperature storage conditions. Store in the original package in order to protect from moisture. Keep the bottle tightly closed.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Vosevi contains
The active substances are sofosbuvir, velpatasvir and voxilaprevir. Each film-coated tablet contains 400 mg sofosbuvir, 100 mg velpatasvir and 100 mg voxilaprevir or 200 mg sofosbuvir, 50 mg velpatasvir and 50 mg voxilaprevir.
The other ingredients are Tablet core: Colloidal anhydrous silica, copovidone, croscarmellose sodium (E468) (see section 2 of this leaflet), lactose monohydrate (see section 2 of this leaflet), magnesium stearate, microcrystalline cellulose (E460)
Film-coating: Iron oxide black (E172), iron oxide red (E172), iron oxide yellow (E172), macrogol (E1521), polyvinyl alcohol (E1203), talc (E553b), titanium dioxide (E171)
What Vosevi looks like and contents of the pack
Vosevi 400 mg/100 mg/100 mg film-coated tablets are beige, capsule-shaped tablets debossed with GSI on one side and 3 on the other side. The tablet is 20 mm long and 10 mm wide.
Vosevi 200 mg/50 mg/50 mg film-coated tablets are beige, oval-shaped tablets debossed with GSI
on one side and SVV on the other side. The tablet is 15 mm long and 8 mm wide.
The tablets are packed in plastic bottles with child resistant caps. Each bottle contains a silica gel desiccant (drying agent) that must be kept in the bottle to help protect your tablets. The silica gel desiccant is contained in a separate sachet or canister and should not be swallowed.
The following pack size is available for both 400 mg/100 mg/100 mg and 200 mg/50 mg/50 mg film- coated tablets:
Marketing Authorisation Holder Gilead Sciences Ireland UC Carrigtohill County Cork, T45 DPIreland
Manufacturer Gilead Sciences Ireland UC IDA Business & Technology Park Carrigtohill County Cork Ireland
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Gilead Sciences Belgium SRL-BV T l/Tel: + 32 (0) 24 01 35 Lietuva Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8
Gilead Sciences Ireland UC .: + 353 (0) 1 686 1Luxembourg/Luxemburg Gilead Sciences Belgium SRL-BV T l/Tel: + 32 (0) 24 01 35 esk republika Gilead Sciences s.r.o. Tel: + 420 910 871 Magyarorsz g Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1Danmark Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1Malta Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1Deutschland Gilead Sciences GmbH Tel: + 49 (0) 89 899890-0
Nederland Gilead Sciences Netherlands B.V. Tel: + 31 (0) 20 718 36 Eesti Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8Norge Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1
Gilead Sciences . . : + 30 210 8930 sterreich Gilead Sciences GesmbH Tel: + 43 1 260 Espa a Gilead Sciences, S.L. Tel: + 34 91 378 98 Polska Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8France Gilead Sciences T l: + 33 (0) 1 46 09 41 Portugal Gilead Sciences, Lda. Tel: + 351 21 7928Hrvatska Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1Rom nia Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1Ireland Gilead Sciences Ireland UC Tel: + 353 (0) 214 825 Slovenija Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1 sland Gilead Sciences Sweden AB S mi: + 46 (0) 8 5057 1Slovensk republika Gilead Sciences Slovakia s.r.o. Tel: + 421 232 121 Italia Gilead Sciences S.r.l. Tel: + 39 02 439Suomi/Finland Gilead Sciences Sweden AB Puh/Tel: + 46 (0) 8 5057 1
Gilead Sciences . . : + 30 210 8930 Sverige Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1Latvija Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8United Kingdom (Northern Ireland) Gilead Sciences Ireland UC Tel: + 44 (0) 8000 113 This leaflet was last revised in
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-9648a8c3d3b260e0c01496efb4b0ef56
Resource Composition:
Generated Narrative: Composition composition-en-9648a8c3d3b260e0c01496efb4b0ef56
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/17/1223/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - vosevi
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp9648a8c3d3b260e0c01496efb4b0ef56
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp9648a8c3d3b260e0c01496efb4b0ef56
identifier:
http://ema.europa.eu/identifier
/EU/1/17/1223/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Vosevi 400 mg/100 mg/100 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en